Company Prepares for Product Distribution Target of $200M Over 5 Years
Ingen Technologies, Inc. (IGNT), Manufacturer of the New "SMART" Oxygen Nasal Cannula for the Home Care Provider Market and Hospital Market, is Featured Side-by-Side With Mid and Large Cap Companies Such as Fisher & Paykel Healthcare Corp. (FPH) and Philips Respironics Inc. in the HME Media Group's "Respiratory & Sleep Management" Web Publication
YUCAIPA, Calif., May 27, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a medical device manufacturer with an emerging new medical product line for the $4 billion U.S. and $8 billion global respiratory market, today announced that it will be featured in the HME Media Group's "Respiratory & Sleep Management" web publication.
"Respiratory & Sleep Management" provides Home Medical Equipment solutions for sleep, oxygen and asthma, with targeted coverage for HME respiratory providers and provocative, clinically-focused articles for home care respiratory therapists. The web publication featured a number of Ingen's products, including its SMART Nasal Cannula, Pulse Oximeter, and Oxyview products and technologies.
View article: http://respiratorysleepmanagement.com/articles/2010/05/14/medtrade-features-respiratory-sleep-innovations.aspx
Ingen Technologies received ISO Certification in 2010 and has recently launched its Ingen Pulse Oximeter. In 2009, the Company added a new dimension to the respiratory healthcare market with the introduction of its new SMART Nasal Cannula Product Line, featuring exclusive Oxyview technology. The Oxyview is a patented in-line pneumatic oxygen flow meter, and since its entry into the respiratory market in late 2007 Ingen has grown to become the largest manufacturer of gravity-independent in-line oxygen flow meters.
"Ingen continues to see strong interest in its leading portfolio of patented technologies designed to address the $8 billion global respiratory market by helping reassure patients and reduce cost for homecare providers," said Ingen CEO Scott Sand. "With new government contracts and certifications in line, we now expect sales to reach $11 million in 2010 and $200 million within the next five years as we continue building value for shareholders."
http://respiratorysleepmanagement.com/pages/about-us.aspx
http://www.smartnasalcannula.com/
http://www.ingenpulseoximeter.com/
About Ingen:
Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.